CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 532 enrolled
Drug / intervention
Shortened duration (6 weeks) of anticoagulant therapy +3 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00687882
NCT00687882Phase 3Completed

Prospective Multi-Center Evaluation of the Duration of Therapy for Thrombosis in Children

Johns Hopkins All Children's Hospital·interventional·Posted Jun 2, 2008·Updated Jun 18, 2025

In Brief

A Phase 3 clinical trial evaluating Shortened duration (6 weeks) of anticoagulant therapy, Conventional duration (3 months) of anticoagulant therapy, and 1 other intervention for Venous Thrombosis. Completed, enrolled 532 participants across 63 sites in 6 countries.

Detailed Summary

The Kids-DOTT trial is a randomized controlled clinical trial whose primary objective is to evaluate non-inferiority of shortened-duration (6 weeks) versus conventional-duration (3 months) anticoagulation in children with first-episode acute venous thrombosis. The first stage of the trial has consisted of a pilot/feasibility component, which then continues as the definitively-powered trial.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Austria, Canada, Israel, Netherlands, United States

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2, 2008
Enrollment StartMar 1, 2008
Primary CompletionJan 5, 2021
Study CompletionFeb 15, 2022
TodayJul 2, 2026
Enrollment to primary: 12.8 yearsPosted 18.1 years ago

Interventions

Shortened duration (6 weeks) of anticoagulant therapyother

Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 6 weeks.

Conventional duration (3 months) of anticoagulant therapyother

Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 3 months.

No Interventionother

Subjects with evidence of persistent thrombus at 6 weeks time will remain on anticoagulant therapy for 3-6 months at the discretion of their treating physician.

No Interventionother

Subjects with evidence of persistent antiphospholipid antibody at 6 weeks will remain on anticoagulant therapy for 3 months to indefinite duration, at the discretion of their treating physician.